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Summary 
 
The maintenance of good health for both body and mind is important for successful aging in 
older individuals. The occurrence of multiple chronic conditions in the same individual causes 
decrements in functional abilities as well as social and psychologic problems that may have an 
impact on many facets of wellbeing and quality of life in the elderly. Among major contributing 
factors to decline in an elderly individual’s health which are common but still poorly understood 
are frailty and cognitive impairment. 
 
Dysregulated hypothalamic-pituitary-adrenal (HPA) axis and, in particular, impaired diurnal 
cortisol secretion is hypothesized as one of the underlying mechanisms for frailty and cognitive 
decline among the elderly. The hypothalamic-pituitary-adrenocortical (HPA) axis is a critical 
adaptive system that maximizes energy mobilization for survival potential in the face of 
physical or psychological challenge. The adrenal hormone cortisol, the end-effector of the HPA 
axis response, acts on multiple organ systems to maintain homeostatic balance. While short-
term exposure to cortisol is beneficial for survival, chronic activation of physiological stress 
responses may lead to serious metabolic, immune, and psychological dysfunction. There is 
growing interest in research relating to the role of specific cortisol circadian rhythmicity in 
influencing various features of health. It is not only the level of circulating cortisol, i.e. either 
hyper- or hyposecretion may induce the onset of diverse pathological conditions by disrupting 
carbohydrate and lipid metabolism, immune response, cardiovascular activity, mood and 
cognitive function, but also its rhythmic activity over the course of a day that plays a significant 
role in human health and disease. However, to date, there is limited epidemiologic evidence of 
the impact of specific cortisol patterns in the elderly. Furthermore, cortisol levels are thought to 
be different in the elderly, due to physiological changes especially in the neuroendocrine system 
of aged individuals.  Thus, further research to examine the impact of specific cortisol secretion 
patterns on health in older age is warranted. 
 
This thesis comprises three publications which are based on data from the population-based 
KORA-Age study. The first publication assessed the associations of frailty phenotype and 
diurnal cortisol secretion pattern in the elderly. Frailty was strongly associated with lower ratios 
of morning to evening cortisol levels. Participants with slow gait speed had increased evening 
cortisol levels whereas participants with low grip strength showed lower morning levels. 
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Additionally, a lower morning to evening ratio was associated with an increased risk of low grip 
strength and gait speed in the total sample population. Increases in evening cortisol were 
associated with an increased risk of being categorized in the pre-frail status. 
 
The second publication assessed the association of cognitive function and salivary cortisol 
secretion patterns in the aged population. Participants with probable dementia and mild 
cognitive impairment (MCI) had lower means of morning after waking (M1) and 30 minutes 
after waking (M2) salivary cortisol levels, and higher late evening cortisol levels compared to 
participants with normal cognition. However, sex-specific significant associations of lower M1 
to E, or M2 to E ratios with increased risk for cognitive impairment were observed among men 
but not women.  
 
The third publication investigated whether sleep disturbances predict cognitive decline in the 
elderly. Cognitive decline was more pronounced in individuals with difficulties maintaining 
sleep (DMS) compared to individuals with no DMS. However, the predictive power of DMS 
was only significant in individuals with normal cognition and not in cognitively impaired 
subjects at baseline. Prolonged sleep duration increased the risk for cognitive decline in 
cognitively impaired individuals. Other sleep characteristics of difficulties initiating sleep (DIS) 
and daytime sleepiness (DS) were not significantly associated with cognitive decline. 
 
In summary, this doctoral thesis provides population-based evidence that dysregulated cortisol 
secretion patterns are central to frailty and cognitive impairment in the elderly, even when 
controlling for known confounders of these disabling outcomes. Sleep disturbances have been 
identified as a potential risk factor of cognitive decline which may offer intervention strategies 
to deter cognitive decline in the elderly with normal cognitive function. Given the relevance of 
cortisol as a stress response hormone in impaired sleep and cognitive decline, thus enforces the 
importance of assisting middle-age and older individuals in stress reduction which is a 
potentially modifiable risk factor. 
  3  
 
Zusammenfassung 
 
Der Erhalt guter körperlicher und geistiger Gesundheit  ist wichtig für erfolgreiches Altern. Das 
Vorkommen von multiplenchronischen Kranheitszuständen in der gleichen Person verursacht 
sowohl Defizite in der Funktionsfähigkeit als auch soziale und psychologischen Problemen, die 
sich auf viele Facetten von Wohlsein und Lebensqualität bei älteren Menschen auswirken 
können. Gebrechlichkeit und kognitive Einschränkung tragen einen großen Teil zu der  
Verschlechterung der Gesundheit bei älteren Menschen bei; trotz ihrer Verbreitung ist aber nur 
wenig über sie bekannt.  
 
Das Nebennierenhormon Cortisol unterliegt dem Regelkreis der HNN-Achse. Es wirkt auf 
mehrere Organssyteme, um das homöostastische Gleichgewicht aufrechtzuerhalten: Mehrere 
Rückkopplungsmechanismen sorgen für eine homöostatische Regulierung der physiologischen 
Reaktionskaskade auf einen Stressor und sorgen für eine sinnvolle Anpassung an aktuelle 
Umweltbedingungen. Während bei akutem Stress ein deutlicher Anstieg des Cortisols erfolgt, 
kann eine längerfristige chronische Belastung sowohl eine Habituation mit verminderter 
Ausschüttung von Cortisol über eine physiologische Veränderung der HHN-Achse als auch eine 
anhaltend ansteigende Ausschüttung bewirken. Die klinischen Folgen einer solchen chronischen 
Belastung und dauerhaften stress-bedingten Aktivierung des Organismus sind von dem Ausmaß 
der Cortisolaus-schüttung abhängig und können zu ernsthaften Stoffwechsel-, Immun- und 
psychologischen Störungen führen. Mit wachsendem Interesse widmet sich die aktuelle 
Forschung der Frage, welche Rolle bestimmte Cortisol-Tagesrhythmen in unterschiedlichen 
Gesundheitsbereichen spielen.  
 
Zum einen können pathologische Veränderungen des zirkulierenden Cortisols, d.h. Hyper- oder 
Hypocortisolismus, durch die damit verbundene Störung des Kohlenhydrat- und 
Lipidstoffwechsel, der Immunantwort, der kardiovaskuläre Aktivität, der Stimmung oder der 
kognitiven Funktionen den Ausbruch diversere Krankheitsbilder begünstigen. Zum anderen 
spielt auch die  rhythmische Cortisolaktivität im Laufe eines Tages eine bedeutsame Rolle in der 
menschlichen Gesundheit. 
 
Dennoch gibt es bisher nur wenige epidemiologische Beweise für die Wirkung spezifischer 
Cortisolsstruktur bei älteren Menschen. Des weiteren geht man davon aus, dass die 
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Cortisolspiegel bei älteren Menschen aufgrund altersbedingter physiologischer Veränderungen 
des neuroendokrinen Systems anders sind. Deshalb sind weitere Forschungsarbeiten nötig, um 
die Wirkung spezifischer Cortisol-Sekretion-Struktur auf die Gesundheit älterer Menschen zu 
untersuchen. 
 
Diese Dissertation besteht aus drei Veröffentlichungen, die auf Daten der bevölkerungsbasierten 
KORA-Age-Studie beruhen. Die erste Veröffentlichung wertete den Zusammenhang zwischen 
Gebrechlichkeit-Phänotyp und Cortisol-Tagesprofil bei älteren Menschen aus. Gebrechlichkeit 
war stark mit einem niedrigeren Verhältnis des Morgen- zum Abendcortisolspiegels assoziiert. 
Teilnehmer mit langsamer Ganggeschwindigkeit hatten erhöhte Abend-Cortisolniveaus, 
während Teilnehmer mit geringer Griffstärke ein niedrigeres Morgenniveau zeigten. Zusätzlich 
war ein niedrigeres Morgen-zu-Abend-Verhältnis mit einem erhöhten Risiko für geringe 
Griffstärke und Ganggeschwindigkeit in der gesamten Stichprobenbevölkerung verbunden. 
Erhöhungen im Abendcortisol waren mit einem erhöhten Risiko verbunden, als „pre-frail“ 
(Vorstufe zur Gebrechlichkeit) klassifiziert zu werden. 
 
Die zweite Veröffentlichung wertete den Zusammenhang kognitiver Funktion und 
Speichelcortisol-Sekretion-Strukturen in den höheren Altersgruppen aus. Teilnehmer mit 
wahrscheinlicher Demenz oder leichte kognitive Beeinträchtigung (LKB) hatte niedrigere 
Mittelwerte von Speichelcortisolspiegeln am Morgen nach dem Aufwachen (M1) und 30 
Minuten nach dem Aufwachen  (M2) sowie höhere Später-Abend-Cortisolspiegl als Teilnehmer 
mit normaler Kognition. Signifikante Zusammenhänge von niedrigen M1-zu-E oder M2-zu-E-
Verhältnissen mit erhöhtem Risiko für kognitive Einschränkung wurden nur bei  
Männernbeobachtet, nicht aber bei Frauen. 
 
Die dritte Veröffentlichung untersuchte, ob Schlafstörungen kognitive Verschlechterung bei  
älteren Menschen prognostizieren. Kognitive Verschlechterung trat häufiger bei Personen mit 
Durchschlafstörungen (DMS) als bei Personen ohne DMS auf. Dennoch war die 
Vorhersagekraft von DMS nur signifikant bei Personen mit normaler Kognition zur Baseline 
und nicht bei Personen mit beeinträchtigter Kognition zur Baseline. Lange Schlafdauer erhöhte 
das Risiko für kognitive Verschlechterung bei kognitivbeeinträchtigten Personen.  
Einschlafstörungen (DIS) und Tagesschläfrigkeit (DS) waren nicht signifikant mit kognitiver 
Verschlechterung verbunden. 
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Zusammenfassend wird in dieser Doktorarbeit anhand bevölkerungsbasierter Daten gezeigt, 
dass gestörte Cortisol-Secretion-Muster erheblich zu Gebrechlichkeit und kognitiver 
Verschlechterung bei älteren Menschen beitragen, sogar nach der Kontrolle für bekannte 
charakteristische Störfaktoren. Schlafstörungen wurden bereits als mögliche Risikofaktoren für 
kognitiver Verschlechterung identifiziert; Interventionsstrategie können hier ansetzen, um die 
kognitive Verschlechterung in älteren Menschen mit normaler kognitiver Funktion abzuhalten. 
Angesichts der Relevanz des Cortisols als ein Stressantwort-Hormon bei gestörtem Schlaf und 
kognitiver Verschlechterung ist es wichtig, Menschen im mittleren und fortgeschrittenen Alter 
Strategien zum Stressabbau an die Hand zu geben, da Stress ein potenziell veränderbarer 
Risikofaktor ist. 
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1. Introduction 
1.1 Hypothalamic-pituitary-adrenal (HPA) axis: cortisol synthesis  
Cortisol, the main glucocorticoid (GC) in man is an end-effector of the hypothalamic-pituitary-
adrenal (HPA) axis activation (Figure 1). The principal effectors of the stress response are 
localized in the paraventricular nucleus (PVN) of the hypothalamus, the anterior lobe of the 
pituitary gland, and the adrenal gland as depicted in Figure 2. This collection of structures is 
commonly referred to as the HPA axis. In reaction to both physical and psychological stress, 
corticotrophin-releasing hormone (CRH) is released from the paraventricular nucleus (PVN) of 
the hypothalamus [1]. Consequently, CRH binds on the type 1 corticotrophin releasing hormone 
receptors (CRH-R1) on the anterior pituitary corticotoph cells stimulating the release of 
adrenocorticotropic hormone (ACTH) from the pituitary gland to the peripheral circulation [2]. 
In turn, ACTH binds to the type 2 melanocortin receptor (MC2-R) in the zona fasciculate cells 
of the adrenal cortex, resulting in the secretion of the steroid hormone cortisol which interacts 
with specific receptors in various target tissues in the brain and periphery [3]. Circulating GC 
ultimately turns off the HPA axis activity and restores a steady state via negative feedback 
mechanisms.  
 
 
Figure 1. Structure of Cortisol [4] 
 
1.2 Cortisol: mechanism and action of the HPA axis  
The HPA axis is a critical adaptive system that maximizes energy mobilization for survival 
potential in the face of physical or psychological challenge [5]. As an end-effector of the stress-
responsive HPA axis, cortisol exerts widespread effects on multiple organ systems to maintain 
homeostatic balance and enable the organism to respond to and cope with physical and 
emotional stressors, aimed primarily at metabolic functioning by increasing energy availability 
in target tissues [6] as well as affecting the immune response [7], and even memory [8] . 
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Besides that, physiological adaptations initiated by activation of this system include increased 
cardiovascular tone, respiratory rate, and intermediate metabolism, along with inhibition of 
general vegetative functions such as feeding, digestion, growth, reproduction, and immunity [6, 
9]. In addition to the HPA axis, several other anatomic structures play important roles in the 
regulation of adaptive responses to stress. These include brain stem noradrenergic neurons, 
sympathetic andrenomedullary circuits, and the parasympathetic systems [10-12]. However, in 
this thesis; we will focus only on HPA axis activation by assessing cortisol secretion levels in 
the aged population. 
 
 
Figure 2 A simplified overview of neuroendocrine regulation of cortisol by the hypothalamic-pituitary 
adrenal (HPA) axis. The influence of stress and circadian rhythm trigger the neurosecretory cells in the 
PVN of the hypothalamus to release CRH which thereby stimulates the ACTH production from the 
pituitary. ACTH then induces the adrenocortical cells to secrete cortisol. Cortisol exerts its actions in 
maintaining various physiological homeostasis in the body. Circulating cortisol inhibits its own 
production both at the hypothalamic and the pituitary level as a negative feedback mechanism. 
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1.3  HPA axis regulation 
The regulatory mechanism in cortisol secretion includes negative feedback mechanism and the 
regulation of circadian rhythm. Cortisol itself plays a vital role in regulating the HPA axis 
through a negative feedback loop which dampens the synthesis and release of CRH and ACTH. 
The negative cortisol feedback inhibition occurs at both pituitary and hypothalamus which 
include fast, delayed or slow feedback time domains [13]. The fast feedback action is within 
seconds to minutes for the rate of GC to increase in plasma following inhibition of stimulated 
ACTH and CRH release, not synthesis occurs when plasma GC levels are increasing [14]. For 
example, cortisol given to patients at the start of surgery attenuates the surgery-induces ACTH 
rise [15]. The delayed feedback occurs within 30 minutes to hours which affects corticotroph 
cells in the pituitary and hypothalamus and occurs after administration of one dose of GC [2, 
16]. Unlike ACTH, CRH synthesis and release may be affected by this delayed feedback [15]. 
The slow feedback takes days or weeks and affects both basal and stimulated HPA axis activity 
and acts via glucocorticoid receptor (GR) mechanisms [13]. It is most important after long 
exposures to a moderately high dose of GC [15]. 
 
Circadian rhythmicity is a physiological hallmark of the dynamic feedback characterized by an 
endogenous oscillation within a near 24-hour period which is generated in the suprachiasmatic 
nucleus of the hypothalamus network [17, 18]. The circadian rhythm helps to adjust our body 
activities to the regular day and night periodicity. As depicted in Figure 3, a strong basal 
cortisol diurnal rhythm is typically characterized by high levels in the morning upon waking, 
which increase 50 - 60% in the first 30 - 45 min after awakening (the cortisol awakening 
response, or CAR). Levels steadily drop over the first few hours after waking, and then slowly 
decline throughout the day reaching nadir at midnight [19, 20].  
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Figure 3. Normal cortisol diurnal rhythm 
 
1.4 Cortisol Awakening Response (CAR) 
The cortisol awakening response (CAR) refers to the sharp increase in cortisol release over the 
first 30 min after awakening [21]. The CAR can be measured as the difference between these 
two cortisol measures (specifically, the value of the 30 - 45 min after awakening sample minus 
the value of the wakeup sample). Another approach is to calculate the area under the curve 
(using the wakeup value as the baseline such that the CAR measure reflects an increase from the 
wakeup value) [22]. Research relating CAR and health showed a number of result discrepancies 
and the exact role of the CAR has still not been fully clarified. Low CAR has been associated 
with chronic health problems, posttraumatic stress and chronic fatigue syndrome while high 
CAR has been related to job stress and general life stress [23]. Adam et al. (2006) have 
suggested that it is an adaptive response aimed to provide the individual with the boost needed 
to meet the anticipated demands of the upcoming day [24]. Likewise, Fries et al. (2009) have 
suggested that the CAR may accompany an activation of prospective memory representations at 
awakening, enabling individuals to orient themselves in space and time, and helping them 
anticipate upcoming demands [21]. It has been suggested that the CAR may be regulated by 
different neurobiological mechanisms than the rest of the underlying diurnal cortisol curve [25]. 
C
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1.5 Late evening cortisol  
Late night saliva samples are generally collected by the patient at the time when the cortisol 
nadir is expected (2300 – 0000 h). An elevated late evening cortisol level has been linked to 
impairment in negative feedback of the HPA axis activation. Several investigators have shown 
that a high late night serum cortisol measurement has excellent diagnostic sensitivity (92 – 
100%) and specificity (92 – 100%) in patients with suspected Cushing’s syndrome [26, 27]. 
Late night salivary cortisol has been shown to have a superior diagnostic performance than 
urinary free cortisol measurement [28]. 
 
Besides the activation of the HPA axis that occurs in true pathologic Cushing’s syndrome (see 
1.7 below), psychiatric disorders (depression, anxiety disorders, and obsessive–compulsive 
disorder), poorly controlled diabetes mellitus and pregnancy are all associated with elevated 
late-night salivary cortisol levels [29-32]. However, increasing age and certain diseases, 
including type 2 diabetes mellitus, result in increased elevated cortisol levels and blunted 
cortisol diurnal variation, and it is not clear if  current thresholds for abnormal late night cortisol 
results can be applied to such populations [32]. Data from KORA-Age population demonstrate 
an age-associated increase in late night salivary cortisol level in the normal, aged population 
[33]. Thus, this must be taken into account when applying traditional cut-off values during 
screening for Cushing’s syndrome.  
1.6 Measures of cortisol diurnal rhythm 
Diurnal cortisol slope is best measured as the rate of decline in cortisol levels across the day, 
typically across the entire span of time from wakening to bedtime. Some researchers prefer to 
measure the diurnal cortisol pattern starting from the peak value of the day, taken 30 - 40 min 
after waking. However, no previous research has explored the ratio of peak morning to evening 
cortisol levels as a representation of the diurnal pattern. Which of these approaches are the most 
meaningful remains to be determined in further research. The minimal protocol for estimating a 
diurnal cortisol slope includes two data points–one in the morning (either wakeup or 30—40 
min post-awakening) and one in the evening, with a slope calculated by subtracting bedtime 
from wakeup values, and dividing by the number of hours separating these two samples [34]. 
Resulting coefficients are negative, reflecting the declining slope of cortisol values [34]. The 
diurnal slope is the most commonly employed cortisol measurement with a steeper decline of 
diurnal slope typically associated with better psychosocial and physical health [34]. A flattened 
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diurnal slope has been shown in elderly subjects with poorer physical performance [35], lower 
cognitive performance [36, 37], type 2 diabetes [38], obesity [39] and who were socially 
isolated [40].  
1.7 Age and sex differences in the HPA axis activation 
In a meta-analysis of 45 studies, Otte et al. found an increased cortisol response to challenge in 
older 
compared to young subjects [41]. A large body of evidence shows that an increased cortisol 
levels are associated with a variety of age-related diseases [41]. The mechanism that accounts 
for increased cortisol responses in the elderly is still unclear. However, according to the 
glucocorticoid cascade hypothesis [42], increased cortisol in the elderly is due to loss of 
mineralo- and glucocorticoid-receptors in the hippocampus, weakening the normal inhibitory 
role of the hippocampus on the HPA axis [43, 44]. The meta-analysis by Otte et al. also revealed 
a three-fold stronger effect of aging on cortisol responses to challenge in women compared with 
men [41]. However, Kudielka et al. provided evidence in a comprehensive review indicating 
that adult men respond to psychological stress with greater increases in cortisol compared to 
women [45]. Although the mechanism is not known, the effect of sex hormones may contribute 
to the increased cortisol response to challenge in women [41]. Thus, focusing on the HPA axis 
may offer novel therapeutic strategies to reduce morbidity in the elderly, albeit with adequate 
sex-specific targets. 
 
1.8 Chronic Stress and Glucocorticoid (GC) Action 
Chronic hypersecretion of cortisol may lead to symptoms known as Cushing’s Syndrome (CS). 
Cushing's syndrome is relatively rare with earlier literature reports an incidence of 2-3 cases per 
million per year [46-48]. However, recent studies of high-risk groups report a significantly 
greater prevalence. Hypercortisolism has been reported in patients with hypertension, 
uncontrolled diabetes, adrenal masses, osteoporosis and vertebral fractures [49-53]. It is 
however still unclear whether the prevalence increase is due to higher-sensitivity testing, a 
higher recognition of disease in high-risk groups, or variability in the diagnostic criteria between 
previous and more-recent studies. 
 
Chronic hypercortisolism may result in the accumulation of visceral fat consequently causing 
adiposity/obesity [54, 55]. GCs increase the activities of enzymes involved in fatty acid 
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synthesis and promote the secretion of lipoproteins [56, 57], induce the hepatic gluconeogenic 
pathway [58], promote the differentiation of preadipocytes to adipocytes, which could lead to an 
increased body fat mass [59], inhibit an insulin-stimulated amino acid uptake by adipocytes 
[60], and increase lipolysis or lipid oxidation which leads to the peripheral insulin resistance 
[61]. Thus, dysregulated cortisol secretion has been shown to be associated with reactive insulin 
hypersecretion, an increasing visceral obesity, and sarcopenia, resulting in dyslipidemia, 
hypertension, and T2DM [62]. Glucocorticoids also directly inhibit pituitary growth hormone, 
gonadotropin and thyrotropin secretion and make the target tissues of sex steroids and growth 
factors resistant to these hormones [63]. Thus, glucocorticoids antagonize the beneficial actions 
of GH and sex steroids on fat tissue (lipolysis) and muscle and bone anabolism [63]. 
 
On the opposite spectrum of Cushing’s syndrome, clinically characterized hypocortisolism or 
primary adrenal insufficiency, also known as Addison’s disease (AD) which can be caused by 
adrenal cortex dysfunction or secondarily a deficiency in pituitary ACTH secretion. The rare 
AD has estimates of prevalences in Caucasians from 39 to 117 per million [64]. Symptoms of 
AD are unspecific but mainly are fatigue, weight loss, hypotension and hypoglycemia and the 
main treatment of AD is with hydrocortisone administration [65, 66]. 
 
1.9 Salivary cortisol as a biomarker in stress research 
Cortisol in saliva is in equilibrium with plasma free cortisol and unlike serum cortisol, is not 
affected in a major way by serum binding proteins. Salivary cortisol levels correlate well with 
the amount of free cortisol in the plasma at the time of collection. Saliva samples are generally 
collected at a specified time whereby subjects may chew a cotton swab which they then place in 
a collection tube. The tube is sealed and transported to the laboratory. Cortisol is rather stable in 
saliva and can be transported by standard postal services at ambient temperature [67]. 
Alternatively, the sampling device or saliva can be frozen for storage and later analysis. Several 
methods are available for the measurement of cortisol in saliva, including radioimmunoassay 
[68], enzyme-linked immunoassay [69], non-isotopic automated immunoassay [70], and liquid 
chromatography–tandem mass spectrometry [68].  
 
The salivary cortisol assessment truthfully follows intra- and interindividual variations in 
plasma, which significantly contributes to its usefulness as a psychophysiological readout [71, 
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72]. This supports salivary cortisol assessment as a reliable measurement to be conducted in a 
population-based setting. Besides that, the integrity of the HPA axis can be evaluated using a 
variety of paradigms in basal and challenge conditions. As an indicator of basal HPA axis 
functioning, the saliva cortisol day curve, the late night measurement, and cortisol awakening 
response (CAR) were assessed in many studies [34]. In addition, neuroendocrine challenge tests 
have been developed to study HPA axis activation including the dexamethasone suppression test 
(DST), which examines whether ACTH production by the pituitary can be inhibited by the oral 
administration of dexamethasone [73]. 
 
Background to the specific topics of the thesis 
1.10 Frailty: epidemiology and risk factors  
Frailty is a multidimensional syndrome characterized by increased vulnerability to stressors as a 
result of cumulative age-related decline in many physiological systems occurring during the 
lifetime. Frail elderly have a substantially increased risk of adverse health outcome including 
falls, disability, long-term care, and mortality [74, 75]. The most commonly used definitions 
were based on physical performance of gait speed, grip strength, unintentional weight loss, and 
sedentary behaviour as well as mental health features of feeling of exhaustion and fatigue [74] 
although cognition [76] and nutrition [77] have been included by others too. 
 
A substantial variation of frailty prevalence rates of 4.0-59.1% were reported in a recent 
systematic review (age ≥ 65 years) which largely explained by the difference in the operational 
definitions for frailty and the study variations [78]. The weighted average prevalence rate was 
9·9% (95% CI 9·6–10·2) for frailty and 44·2% (44·2–44·7) for pre-frailty [78] in studies that 
used the phenotype model. Frailty was more prevalent in women than in men and steadily 
increasing with age: 65–69 years 4%; 70–74 years 7%; 75–79 years 9% 80–84 years 16%; older 
than 85 years 26% [78]. Most frailty models were developed in Caucasian populations, and the 
prevalence of frailty might be higher in people living in southern Europe [79] and in elderly 
Hispanic and African–American populations [80]; therefore, different cutoffs might be 
necessary for assessing frailty in different populations.  
 
Neuroendocrine alterations are thought to be involved in the etiology of frailty, but have not 
been well characterized in previous studies which were limited to either sex-specific samples or 
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study size [81, 82]. Recent meta-analysis demonstrated associations between greater diurnal 
cortisol decline and gait speed [35]. A link between hypercortisolism and frailty is plausible due 
to the association of high cortisol levels and increased catabolism, leading to loss of muscle 
mass, anorexia, weight loss, and reduced energy expenditure, all of which are key clinical 
features of frailty [83]. Thus, frailty manifests as the failure in homeodynamic cycles around 
energy metabolism and neuromuscular changes with alteration in protein synthesis leading to 
sarcopenia. Increased rates of sarcopenia has also been shown in diabetes-related physical 
frailty [84]. 
1.11 Cognitive impairment: epidemiology and risk factors 
Cognitive impairment is the decline of intellectual functions which covers various functional 
domains mainly orientation, memory, attention or calculation and language.  The effects range 
from mild forms termed as mild cognitive impairment (MCI) that is not accompanied by any 
significant functional dis-ability and defines a transitional stage of between normal cognitive 
function and dementia [85]. Dementia is characterized by severe cognitive which is enough to 
compromise social and/or occupational functioning [85]. 
 
Prevalence of dementia increases exponentially with increasing age, and doubles every five 
years of age after age 65 [85].  In higher income countries, prevalence is 5–10% in those aged 
65+ years and generally greater among women than among men, due to longer life expectancy 
of women than men [85]. Risk factors including lower education, hypertension, high 
cholesterol, high body mass index (BMI) and disease conditions of cardiovascular diseases, 
coronary heart diseases, stroke and obstructive sleep apnea are associated with increased risk of 
dementia in late life [85]. Psychological risk factors which are associated with increased risk of 
dementia are depression, anxiety, post-traumatic stress disorder. The Apolipoprotein E (APOE) 
gene polymorphism on Chromosome 19 has been identified as increasing susceptibility for 
dementia as well as Alzheimer’s disease [86, 87]. 
 
Dysregulation of the HPA axis by psychological stress, which results in chronically high 
cortisol exposure of the hippocampus, is proposed to contribute to cognitive decline in the 
elderly [88]. An elevated circulating level of cortisol has been implicated in the pathogenesis of 
cognitive impairment through detrimental effects of glucocorticoids on hippocampal neurons 
[88, 89]. Apart from the damage in the hippocampal and prefrontal region through GC receptor-
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mediated effects, altered glucose transport into the brain has a key role in the underlying 
mechanism of decline in cognitive function [90]. Thus, there is a link between HPA axis 
dysfunction, cognitive impairment and metabolic dysregulation leading to type 2 diabetes. 
1.12 Sleep and cognitive decline 
Sleep is a complex behavioral state that occupies one-third of the human lifespan. Many studies 
have identified the protective factors influencing sleep that could be grouped under three broad 
categories, namely socioeconomic, behavioral, and nutritional [91]. There is growing evidence 
on a potential role of good sleep quality as one of the modifiable risk factor of cognitive decline 
[92]. Sleep was thought to be important primarily for restoring brain function. However, 
increasing evidence suggests that sleep also modulates the metabolic, endocrine, immune and 
cardiovascular systems. Sleep is regulated by a homeostatic factor and by a circadian factor, 
which facilitates falling asleep in the evening [93]. Interactions between sleep and the circadian 
clock regulate hormonal control including the HPA axis with cortisol [94]. In a systematic 
review, prospective studies have identified female gender, depressed mood, and physical illness 
as general risk factors for future sleep disturbances in later life [95]. Alterations in hormonal 
profiles in aging process are linked to the development of cognitive impairment, through the 
inability of the body to return to a basal condition of homeostasis after stressful conditions [96]. 
Therefore, sleep quality plays a role on the neuroendocrine activity which allows for the optimal 
regulation of the hormonal homeostasis [97]. 
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2. Rationale and methods  
2.1 Specific aims 
The thesis is based on the hypothesis that dysregulated cortisol secretion, represented by 
specific cortisol levels taken at various times during the day, is related to the frailty phenotype 
and cognitive impairment in the elderly.  We also explored the role of impaired sleep patterns in 
predicting cognitive decline in a prospective analysis with a 3-year follow up in the aged 
population.  
 
The specific objectives were: 
 
Manuscript 1: to examine the association between salivary cortisol secretion and frailty 
phenotype in a representative elderly population of KORA-Age. 
 
Manuscript 2: to assess the association between salivary cortisol and cognitive function in a 
representative elderly population of KORA-Age. 
 
Manuscript 3: to investigate whether major patterns of poor sleep (difficulties in initiating 
sleep (DIS), difficulties in maintaining sleep (DMS) or both DIS and DMS, daytime sleepiness, 
and sleep duration) were associated with cognitive decline in a population-based sample of 
older adults over 3 years of follow up. 
 
2.2 Study population 
The data in this cumulative thesis stem from the KORA (Cooperative Health Research in the 
Region of Augsburg)-Age study which was a follow-up study of the four MONICA/KORA 
Augsburg Surveys, conducted between November 2008 and November 2009 [98]. All 
participants, aged 64 years or older, were selected from a population-based random sample (N = 
5991) of the previous surveys (Survey 1-4, conducted between 1984 and 2001 in the Augsburg 
region, Southern Germany) as displayed in Figure 4, with participation rates ranging between 
67% and 79% [98]. In total, 4127 people participated in a standardized telephone interview. Out 
of this group, a randomly drawn sample of 1079 participants additionally underwent extensive 
physical examinations including collection of blood samples, anthropometric examination, and a 
personal interview.  In 2012, a re-examination was performed in 822 persons (84.3% of all 
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eligible persons). Both baseline and follow-up surveys included a telephone and personal 
interview and a physical examination which assessed somatic and mental health related 
multimorbidity. 
 
Figure 4.  KORA-Age study and the previous MONICA/KORA surveys (1-4)   
 
For the analysis of manuscript 1 and 2, only participants who provided complete, salivary 
samples (N = 772, saliva sampling rate of 72%) were included. The final data set for manuscript 
1 consisted of 722 participants (382 males and 363 females) aged 65 to 89 years (mean age =75 
years) and manuscript 2 consisted 733 participants (375 males and 358 females) aged 65 to 89 
years (mean age =75 years). For manuscript 3, a total of 740 study participants (men=49 %, N= 
366, women 51%, N=374, mean age=75 years (range 64-94 years) with complete data on 
baseline covariates and cognitive status as well as cognitive status at follow up were included in 
the study. The KORA-Age study was approved by the Ethics Committee of the Bavarian 
Medical Association and all participants provided a written informed consent. 
2.3 Statistical analyses 
Manuscript 1 uses multiple linear regression models to assess the association of frailty counts 
and cortisol levels (morning after awakening (M1), 30 minutes after awakening (M2), late 
evening (E), ratio of M1 to E (M1/E), and ratio of M2 to E (M2/E)). All covariates and cortisol 
measures were entered into a multinomial logistic regression model with the outcome frailty to 
distinguish the risk of being frail or pre-frail (as opposed to non-frail) and then we further 
employed a logistic linear regression with the outcome of each specific frailty criteria (weight 
loss, exhaustion, physical inactivity, walking speed and Timed Up and Go test).  
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In manuscript 2, cortisol measures and important covariates, with the outcome cognitive 
(TICS-m) score were entered into a multiple linear regression model to assess the effect of 
cortisol levels on the risk of increased cognitive score. A sex-stratified multiple variable linear 
regression analysis was also considered. An additional multinomial logistic regression analysis 
was computed with a categorical cognitive status variable as the outcome, to distinguish the risk 
of being mildly cognitively impaired or probably demented (as opposed to having normal 
cognitive function).  
 
In manuscript 3, we employed multiple linear regressions to analyze the association between 
various patterns of poor sleep (main exposure) and cognitive change (continuous outcome) after 
3 years of follow up. Three distinct patterns of poor sleep (sleep difficulties at night (DIS, DMS 
and both), daytime sleepiness, and sleep duration) and the total sum score of all sleep domains 
were considered in separate regression models. We then examined the interaction of the effect 
of any of the three patterns of poor sleep with baseline cognitive status on cognitive decline, by 
including the product of both variables in a fully adjusted model (adjusted for age, sex, baseline 
cognitive score, smoking status, alcohol consumption, physical activity, depressive symptoms, 
hypertension, and somatic co-morbidities).  
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3. Results 
3.1 Manuscript 1: Blunted diurnal cortisol pattern is associated with frailty: a cross-
sectional study of 745 participants aged 65 to 90 years (H. Johar et al., Journal of Clinical 
Endocrinology and Metabolism, 2014) 
In manuscript 1, lower cortisol levels in the morning after awakening sample (M1) (P =0.18) 
and 30 minutes after awakening, M2 (P = 0.14) and increased evening cortisol levels (P = 
0.004) were observed in pre-frail (35.17%, n=262) and frail (3.36%, n=25) individuals, in a 
dose-response manner. Frailty was strongly associated with smaller ratios of morning to evening 
levels; M1 to E ratio (P=0.02) and M2 to E ratio (P=0.003). Higher evening cortisol levels were 
associated with a 24% increased risk of a pre-frail state (odds ratio, 1.22; 95% confidence 
interval, 1.03–1.44). In fully adjusted multinomial logistic regression models calculated for each 
of the 5 individual frailty criteria as outcome, an increased risk of low gait speed was associated 
with increasing evening cortisol levels (1.35, 1.10–1.65, per 1-standard deviation  (SD) increase, 
P = 0.004) as well as the ratio M2/E (1.42, 1.09–1.86, P = 0.01). A 51% increased risk of low 
physical activity was associated with an increase in CAR (1.51, 1.14–2.01, P = 0.004), and risk 
of low grip strength was associated with both ratios of M1/E (1.36, 1.03–1.79, P = 0.03) and 
M2/E (1.31, 1.02–1.68, P = 0.04).  
 
3.2 Manuscript 2: Lower morning to evening cortisol ratio is associated with cognitive 
impairment in men but not women: An analysis of 733 older subjects of the cross-sectional 
KORA-Age study. (H. Johar et al., Psychoneuroendocrinology, 2015) 
In manuscript 2, a dose response finding was observed with lower morning (M1 and M2), and 
increased evening levels in participants with probable dementia (4.5%, N = 33) and slightly 
increased in mildly cognitive impaired (MCI) (13.8%, N = 101) compared to healthy 
individuals. Higher morning to evening ratios were associated with reduced odds of cognitive 
impairment, even after adjustments for important confounders (M1/E ratio: OR = 1.50, 95% CI 
= 1.08—2.07, M2/E ratio: 1.41, 1.01—1.95, per 1-SD increase). In a sex-stratified analysis, M1, 
M2, E levels and both ratios of M1/E and M2/E levels were significantly associated with 
cognition in men and not women. In fully adjusted model, higher M1/E and M2/E ratios were 
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significantly associated with increased odds of better cognition (M1/E: OR = 1.94, 95%CI = 
1.24—3.02, P= 0.004; M2/E = 1.74, 1.12—2.71, 0.01) in men but not women (M1/E = 1.11, 
0.69—1.78, 0.67; M2/E = 1.09, 0.67—1.77, 0.74). 
 
3.3 Manuscript 3: Impaired Sleep Predicts Cognitive Decline in Old People: Findings 
from the Prospective KORA Age Study. (H. Johar et al., SLEEP, 2015) 
Using a prospective analysis approach, manuscript 3 investigated the predictive role of poor 
sleep patterns with cognitive decline. In this investigation, participants who reported problems 
maintaining sleep (n=211) were more likely to have a decline in their cognitive score after 3 
years compared to those who reported no DMS at baseline (fully adjusted model, β=0.88, 
95%CI=0.03-1.74, P = 0.04). Given the significant interaction between cognitive decline and 
sleep disturbances (DMS*baseline cognitive status, P=0.04), we further stratified our analyses 
according to normal or impaired cognitive status at baseline. DMS was significantly associated 
with cognitive decline only in participants with normal cognitive status and not in cognitively 
impaired individuals.   In a fully adjusted model, cognitive decline was 1.3-points larger in 
cognitively normal individuals with DMS compared to individuals with no sleep disturbances 
(β=1.26, 95%CI=0.35-2.18, P=0.007) whereas the effect in cognitively impaired participants 
was not statistically significant in the model (β=0.06, 95%CI=-2.23-2.35, P=0.96). 
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4. Conclusion and outlook 
 
Psychological stress, by the activation of the HPA axis, plays a key role in the development 
of frailty and cognitive impairment. This thesis presented novel findings on the detrimental 
effects of dysregulated cortisol, in specific cortisol secretion patterns, on two important age-
related conditions, namely the frailty syndrome and cognitive function as presented in 
manuscripts 1 and 2, respectively. Firstly, this thesis confirms and expands the view that 
blunted diurnal cortisol responses were observed in both men and women with increasing 
frailty burden. Findings from manuscript 1 successfully identify that the lack of diurnal 
variability, as reflected by a lower morning to evening cortisol ratio, is associated with frailty 
burden. Our observations support the predominant role of muscle atrophy, reflected in the 
grip strength and gait speed criteria, and cortisol dysregulation even in the pre-frail state.   
 
Secondly, manuscript 2 similarly highlights the role of reduced diurnal variability with lower 
morning and higher evening cortisol levels in the pathophysiological mechanism of cognitive 
impairment in the elderly. However, the significant association of an increased risk for 
cognitive impairment was observed among men but not women. A blunted diurnal cortisol 
pattern appears to be a sensitive measure of decreased HPA axis resilience that leads to 
diminished cognition that can be observed even in MCI individuals. In the same vein of 
manuscript 1, the simple morning to evening cortisol level ratios which is relatively 
unexplored, were sensitive to detect an association of impaired HPA axis functioning and 
cognition. Thus, it is important to assess the clinical relevance of the morning and evening 
cortisol balance as a therapeutic target. Since the nature of cross-sectional studies of both 
manuscript 1 and 2 cannot infer causality, a prospective analysis of the study population is 
warranted.  
 
Cortisol is essentially involved in many physiological processes mainly aimed at energy 
mobilization.  Energy metabolism and increases in proinflammatory cytokines are potential 
biological mechanisms which are shared by both frailty and cognitive dysfunction.  
Alterations in protein synthesis and protein breakdown in muscles lead to an increased rate 
of muscle mass loss is related to diabetes [84]. Damage in the hippocampal and prefrontal 
area through GC receptor-mediated effects and by affecting glucose transport into the brain 
are also linked to type 2 diabetes [90]. Diabetes is a relevant midlife epidemic that 
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predisposes individuals to frailty and cognitive decline [4, 67] . Thus, we further investigate 
the link between cortisol secretion patterns, type 2 diabetes and glycemic control in the 
KORA-Age population and found an elevated late evening cortisol patterns in subjects with 
type 2 diabetes as well as sex-specific association of enhanced Cortisol Awakening 
Response (CAR) in men [99]. We also found that the association of higher CAR in men was 
influenced by central adiposity [99]. Overall, the impact of dysregulated cortisol secretion on 
frailty and cognition is likely a consequence of a multitude of interrelated factors, of which 
only some have been evaluated within the scope of this dissertation. In addition, longitudinal 
data of the 3 year follow up of KORA-Age 2 will provide further insight into the order of 
events with respect to HPA axis abnormalities.  
 
As a result of the important link between HPA axis and cognitive function, findings from the 
prospective analysis in manuscript 3 confirm and extend the existing literature on the role of 
sleep as a modifiable risk factor for cognitive decline. Sleep is important primarily for 
restoring brain function as well as modulating metabolic, endocrine and cardiovascular 
system. Furthermore, sleep deprivation is a clear example of a stressor which has detrimental 
effects on HPA activity [96]. Given the close relationship between frailty and cognitive 
function [100], sleep has been also suggested recently to play a role in muscle protein 
metabolism [101]. Reductions in sleep quality and duration as well as increases in 
prevalence of circadian-related sleep disorders with age favor proteolysis, altered body 
composition, and increase the risk of insulin resistance, all of which have been associated 
with sarcopenia and frailty. 
 
In conclusion, this thesis has outlined the underlying psychoneuroendocrinology mechanism 
leading to frailty and cognitive impairment as well as sleep deprivation as a potential 
contributor leading to cognitive decline in the elderly. Furthermore, understanding the link 
between frailty and cognitive function has implications for the management of elderly 
patients. Alterations in cortisol secretion patterns that occur during the aging process are 
implicated in the development of frailty and cognitive impairment through a variety of 
mechanisms involving the adaption to stressful conditions. Stressful experiences increase 
levels of stress hormones in older individuals who may be less resilient, and unable to return 
to basal conditions of homeostasis. Moreover, non-pharmacological stress management and 
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lifestyle interventions have shown beneficial to improve the well-being of pre-frail and MCI 
individuals, as well as to improve sleep quality and overall health in the elderly [102-104]. 
 
The novel morning to evening cortisol ratio as a marker of HPA axis activity may provide 
crucial information about the underlying mechanism of frailty and cognitive impairment. 
The ability to identify pre-frail and MCI individuals requires more attention as these elderly 
people, who are most at risk for worse prognoses, are a critical target for intervention 
strategies. Moreover, the identification of impaired sleep quality is critically important for 
optimal maintenance of health in older age.  Finally, future research should focus more on 
the relevant role of chronic exposure of psychological stress leading to the activation of HPA 
axis in order to better understand the underlying biological mechanism of adverse age-
related conditions. Our current understanding on the association between chronic stress, 
HPA axis dysregulation and metabolic dysregulation which includes type 2 diabetes and 
obesity, both linked by inflammation, opens new research avenues that we hope to proceed 
in near future. Furthermore, we plan to incorporate dynamic and multivariate methods for 
assessing links between stressors and other potential neuroendocrine biomarkers of 
dehydroepiandrosterone sulfate (DHEAs), insulin-like growth factor (IGF) and melatonin in 
our future work endeavors.  
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Supplementary table 1: Associations of various cortisol measurements at specific time-
points with cognitive impairment   (Reference=normal) (N=733) 
Cortisol 
Measurements 
MCI vs. Normal Probable Dementia vs. Normal 
OR, 95% CI p-value OR, 95% CI p-value 
M1 0.82 (0.67-1.00) 0.05 0.87 (0.63-1.22) 0.42 
M2 0.84 (0.68-1.03) 0.09 0.85 (0.62-1.18) 0.33 
E 1.12 (0.90-1.38) 0.32 1.29 (0.92-1.81) 0.13 
M1/E 0.74 (0.57-0.96) 0.02 0.66 (0.43-1.02) 0.06 
M2/E 0.77 (0.60-0.99) 0.04 0.67 (0.45-1.00) 0.05 
CAR 0.98 (0.53-1.82) 0.95 0.85 (0.29-2.49) 0.77 
 
 
- adjusted for age, sex, physical activity, alcohol intake, frailty, sleep and depressive symptoms with the 
outcome of cognitive status as measured by TICS-m (adjusted by education)  
- Odds ratio (OR) is for a 1 standard deviation (SD)  increase of cortisol level (SD of logM1 = 0.61, 
logM2 = 0.62, logA = 0.69,  log(M1/E) = 0.83, log(M2/E) = 0.86, CAR = 2.99) 
- Abbreviations:  M1=Morning after waking, M2=30 minutes after waking, E=Evening, CAR=Cortisol 
Awakening Response, MCI = Mild Cognitive Impairment 
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